On Wednesday, KeyBanc Capital Markets updated its rating on Health Catalyst Inc. (NASDAQ:HCAT), elevating the stock from Sector Weight to Overweight and setting a new price target of $9.00.
Currently trading at $6.98, the stock has received positive attention from analysts, with InvestingPro data showing six analysts revising their earnings estimates upward for the upcoming period.
The adjustment follows KeyBanc's analysis of credit card data indicating sustained healthy utilization levels, which is anticipated to positively influence hospital technology budgets.
The firm also cited the early stages of margin expansion leading to healthier technology revenue growth as a contributing factor to the upgrade. According to KeyBanc, these developments are occurring alongside a deeply discounted valuation of Health Catalyst shares, which are currently trading at approximately 1.0x FY25 revenues.
This is notably lower than the peer average, which is closer to 2.0x. InvestingPro's Fair Value analysis suggests the stock is currently undervalued, supporting KeyBanc's assessment.
KeyBanc's optimism is further supported by Health Catalyst's financial outlook, with the company expected to achieve an annual growth rate of 12% and reach mid-teens adjusted EBITDA margins by the following year.
The company has already demonstrated progress with a 4.15% revenue growth in the last twelve months, and InvestingPro's Financial Health Score rates the company as "GOOD."
The firm's analysis suggests that Health Catalyst's current market position and financial trajectory present a favorable opportunity for investors. Discover more insights about HCAT and 1,400+ other stocks with InvestingPro's comprehensive research reports.
The upgrade to Overweight is a signal of KeyBanc's confidence in Health Catalyst's potential for growth and profitability. This perspective is bolstered by the company's performance metrics, which appear to be improving in comparison to its industry peers.
In other recent news, Piper Sandler, showing optimism for the company's performance, raised the price target on Health Catalyst's stock to $12.00 from a previous $11.00, based on the revised calendar year 2024 guidance provided by Health Catalyst.
In addition to these analyst upgrades, Health Catalyst disclosed its third-quarter financial results for 2024, indicating a positive profit and loss execution and a revenue mix shifting back towards software. The company's leadership team expressed a positive outlook for Health Catalyst's growth trajectory and provided financial projections for the remainder of 2024 and the full year of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.